AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19436693 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg bid
Number of subjects: 6800
Study 17097394 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA1 (20 U)
Number of subjects: 62
Study 17097394 — intervention group
Group type: COMPARATOR
Intervention: BoNTA2 (50 U)
Number of subjects: 62
Study 14767589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program (6-week self-help manual)
Number of subjects: 104
Study 14767589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 104
Study 11589758 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 50 Hz magnetic field exposure (100 microT rms)
Number of subjects: 21
Study 11589758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent 50 Hz magnetic field exposure (100 microT rms)
Number of subjects: 21
Study 11589758 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (no magnetic field)
Number of subjects: 21
Study 9508204 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF 125 microg/m2 per day for 8 days
Number of subjects: 399
Study 9508204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 7905041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 7
Study 2537787 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabi 2165, 2,500 anti‐Xa units twice a day (group A)
Number of subjects: 124
Study 2537787 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabi 2165, 2,500 anti‐Xa units twice a day during the first 48 h postoperatively and then 5,000 anti‐Xa units once a day (group B)
Number of subjects: 124
Study 2537787 — intervention group
Group type: COMPARATOR
Intervention: Adjusted-dose standard heparin, monitored by activated partial thromboplastin time (group C)
Number of subjects: 124
Study 4934187 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 730
Study 4934187 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 730
Study 31850603 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 712
Study 31850603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-replacement therapy (NRT)
Number of subjects: 712
Study 31850603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 712
Study 31850603 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 712
Study 29863535 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted ILM flap technique
Number of subjects: 24
Study 29863535 — intervention group
Group type: COMPARATOR
Intervention: Conventional ILM peeling (ILMP group)
Number of subjects: 24
Study 29099972 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanesthetic dose of ketamine
Number of subjects: 68
Study 29099972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 26665676 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dapoxetine on demand
Number of subjects: 117
Study 26665676 — intervention group
Group type: COMPARATOR
Intervention: 50 mg sertraline qd for one month
Number of subjects: 117
Study 23702146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling plus administration of a commercially available Ca(2+) and VitD supplementation product
Number of subjects: 150
Study 23702146 — intervention group
Group type: COMPARATOR
Intervention: Dietary counseling alone
Number of subjects: 150
Study 21244348 — intervention group
Group type: EXPERIMENTAL
Intervention: AD patient management program (PLASA study)
Number of subjects: 1131
Study 21244348 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1131
Study 21244348 — intervention group
Group type: COMPARATOR
Intervention: LOCF analysis
Number of subjects: 1131
Study 21244348 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation, longitudinal mixed effects models, z-score LOCF
Number of subjects: 1131
Study 19154992 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Supported Employment (ISE) program
Number of subjects: 163
Study 19154992 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement & Support (IPS)
Number of subjects: 163
Study 19154992 — intervention group
Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 163
Study 17216347 — intervention group
Group type: EXPERIMENTAL
Intervention: FF-MAS 5 microM
Number of subjects: 365
Study 17216347 — intervention group
Group type: EXPERIMENTAL
Intervention: FF-MAS 20 microM
Number of subjects: 365
Study 17216347 — intervention group
Group type: COMPARATOR
Intervention: Inert control
Number of subjects: 365
Study 15530627 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal assessment
Number of subjects: 43219
Study 15530627 — intervention group
Group type: EXPERIMENTAL
Intervention: Management by geriatric team
Number of subjects: 43219
Study 15530627 — intervention group
Group type: COMPARATOR
Intervention: Targeted assessment
Number of subjects: 43219
Study 15530627 — intervention group
Group type: COMPARATOR
Intervention: Management by primary-care team
Number of subjects: 43219
Study 11396283 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume BAL (mean volume: 131 +/- 14 ml)
Number of subjects: 37
Study 11396283 — intervention group
Group type: COMPARATOR
Intervention: Low volume BAL (40 ml volume for all patients)
Number of subjects: 37
Study 11396283 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high volume and low volume BAL
Number of subjects: 37
Study 9632272 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood progenitor cell transplantation (PBPCT)
Number of subjects: 66
Study 9632272 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 66
Study 9632272 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 66
Study 8143994 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran supplement (13-15 g for 8 weeks)
Number of subjects: 48
Study 8143994 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran supplement (13-15 g for 8 weeks)
Number of subjects: 48
Study 8143994 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn bran supplement (13-15 g for 8 weeks)
Number of subjects: 48
Study 8143994 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 48
Study 3175057 — intervention group
Group type: EXPERIMENTAL
Intervention: Married client
Number of subjects: 43
Study 3175057 — intervention group
Group type: COMPARATOR
Intervention: Unmarried client
Number of subjects: 43
Study 31554005 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 314
Study 31554005 — intervention group
Group type: COMPARATOR
Intervention: Naftopidil 75 mg
Number of subjects: 314
Study 28606893 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel the ViBe (FtV) + usual care
Number of subjects: 93
Study 28606893 — intervention group
Group type: COMPARATOR
Intervention: Minimally enhanced usual care
Number of subjects: 93
Study 25913022 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (target temperature, 33.0°C)
Number of subjects: 295
Study 25913022 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic normothermia (target temperature, 36.8°C)
Number of subjects: 295
Study 25913022 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 295
Study 25913022 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic normothermia
Number of subjects: 295
Study 25913022 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 295
Study 23265177 — intervention group
Group type: EXPERIMENTAL
Intervention: SSCT (Single-source CT)
Number of subjects: 180
Study 23265177 — intervention group
Group type: EXPERIMENTAL
Intervention: HPCT (High-pitch CT)
Number of subjects: 180
Study 23265177 — intervention group
Group type: EXPERIMENTAL
Intervention: DECT (Dual-energy CT)
Number of subjects: 180
Study 23265177 — intervention group
Group type: COMPARATOR
Intervention: SSCT vs DECT
Number of subjects: 180
Study 23265177 — intervention group
Group type: COMPARATOR
Intervention: HPCT vs DECT
Number of subjects: 180
Study 21699796 — intervention group
Group type: EXPERIMENTAL
Intervention: RFSP slope ≥ 0.2 in group A (95 patients, 27.6%)
Number of subjects: 457
Study 21699796 — intervention group
Group type: COMPARATOR
Intervention: RFSP slope < 0.2 in group A (249 patients, 72.4%)
Number of subjects: 457
Study 18083750 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 33
Study 18083750 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin treatment)
Number of subjects: 33
Study 18083750 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (combined analysis)
Number of subjects: 33
Study 15806046 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (110% motor threshold; 1 Hz; 2000 stimuli/day over 5 days)
Number of subjects: 14
Study 15806046 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (placebo control)
Number of subjects: 14
Study 12691821 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-irradiation with 17 fractions of 1.8 Gy, 5 days a week (N=15, group A)
Number of subjects: 30
Study 12691821 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-irradiation with 4 Gy plus two fractions of 3 Gy the 1st week and six fractions of 3 Gy given every second day (N=15, group B)
Number of subjects: 30
Study 12691821 — intervention group
Group type: COMPARATOR
Intervention: Comparison of radiation schedules between group A and group B
Number of subjects: 30
Study 10426972 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic valvulotome
Number of subjects: 20
Study 10426972 — intervention group
Group type: COMPARATOR
Intervention: Metal valvulotome
Number of subjects: 20
Study 7568860 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol, 320/150/48
Number of subjects: 111
Study 7568860 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol, 300/150/45
Number of subjects: 111
Study 7568860 — intervention group
Group type: COMPARATOR
Intervention: ioversol, 320/100/32
Number of subjects: 111
Study 7568860 — intervention group
Group type: COMPARATOR
Intervention: ioversol, 300/100/30
Number of subjects: 111
Study 2306750 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 10-15 mg (mean dose of 13 mg)
Number of subjects: 7
Study 2306750 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg (single dose)
Number of subjects: 7
Study 6254720 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg intravenous clonidine after pretreatment with 300 mg cimetidine
Number of subjects: 6
Study 6254720 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg intravenous clonidine after pretreatment with 0.8 mg naloxone
Number of subjects: 6
Study 6254720 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg intravenous clonidine after pretreatment with saline
Number of subjects: 6
Study 30982411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training (high-difficulty and low-difficulty)
Number of subjects: 50
Study 30982411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training (high-difficulty)
Number of subjects: 50
Study 30982411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training
Number of subjects: 50
Study 30982411 — intervention group
Group type: COMPARATOR
Intervention: Single-task training
Number of subjects: 50
Study 29779961 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative discussion and review of images (CT image or angiogram)
Number of subjects: 51
Study 29779961 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative discussion
Number of subjects: 51
Study 27224454 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) regimens for prevention of mother-to-child transmission during breastfeeding
Number of subjects: 677
Study 27224454 — intervention group
Group type: COMPARATOR
Intervention: Urban location
Number of subjects: 677
Study 27224454 — intervention group
Group type: COMPARATOR
Intervention: Salaried employment or being a student
Number of subjects: 677
Study 27224454 — intervention group
Group type: COMPARATOR
Intervention: Infant hospitalization before weaning
Number of subjects: 677
Study 25012765 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg/day in 3 divided doses) + Raloxifene (120 mg/day)
Number of subjects: 46
Study 25012765 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (6 mg/day in 3 divided doses) + Placebo
Number of subjects: 46
Study 22210632 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 4996
Study 22210632 — intervention group
Group type: COMPARATOR
Intervention: Control (uncircumcised men)
Number of subjects: 4996
Study 22210632 — intervention group
Group type: COMPARATOR
Intervention: Control (circumcised men)
Number of subjects: 4996
Study 20483042 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab therapy
Number of subjects: 8
Study 20483042 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 8
Study 20483042 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 8
Study 17909753 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (0, 6, or 12 mg/70 kg, i.m.)
Number of subjects: 10
Study 17909753 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (0, 1, 3, 10, or 30 mg, p.o.)
Number of subjects: 10
Study 17909753 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone pretreatment with Butorphanol
Number of subjects: 10
Study 17909753 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (various doses)
Number of subjects: 10
Study 16441799 — intervention group
Group type: EXPERIMENTAL
Intervention: co-phenylcaine (lignocaine 5% with phenylephrine)
Number of subjects: 30
Study 16441799 — intervention group
Group type: COMPARATOR
Intervention: lignocaine 5% spray
Number of subjects: 30
Study 14595042 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPAP
Number of subjects: 162
Study 14595042 — intervention group
Group type: EXPERIMENTAL
Intervention: IF CPAP
Number of subjects: 162
Study 11247401 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric respiratory exercises method applied for 24 days
Number of subjects: 124
Study 11247401 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children living in Upper Silesia industrial region)
Number of subjects: 124
Study 11247401 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric respiratory exercises method
Number of subjects: 124
Study 8612105 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program over 22 weeks
Number of subjects: 160
Study 8612105 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 160
Study 1451713 — intervention group
Group type: COMPARATOR
Intervention: DoBe (L-Dopa + benserazide)
Number of subjects: 587
Study 1451713 — intervention group
Group type: EXPERIMENTAL
Intervention: DoBeBro (L-Dopa + benserazide + bromocriptine)
Number of subjects: 587
Study 6144317 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 150
Study 6144317 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 150
Study 6144317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 150
Study 6144317 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 150
Study 6144317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 31141551 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruments used to assess the quality of clerkship rotations from the perspective of students
Number of subjects: 49
Study 31141551 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruments containing questions about the ethical domain
Number of subjects: 49
Study 31141551 — intervention group
Group type: EXPERIMENTAL
Intervention: Questions about negative experiences concerning the ethical domain
Number of subjects: 49
Study 31141551 — intervention group
Group type: EXPERIMENTAL
Intervention: Questions about witnessing patient mistreatment
Number of subjects: 49
Study 31141551 — intervention group
Group type: EXPERIMENTAL
Intervention: Questions about mistreatment against students
Number of subjects: 49
Study 30121018 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful decongestion by hemodynamics (right atrial pressure ≤8 mmHg and/or wedge pressure ≤15 mmHg at discharge)
Number of subjects: 433
Study 30121018 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful decongestion by clinical exam (≤1 sign of congestion at discharge)
Number of subjects: 433
Study 30121018 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful decongestion by hemoconcentration (any increase in hemoglobin)
Number of subjects: 433
Study 30121018 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful decongestion by estimated plasma volume (5% reduction in plasma volume)
Number of subjects: 433
Study 30121018 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital worsening renal function (WRF) among patients decongested at discharge
Number of subjects: 433
Study 28717702 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine once per day
Number of subjects: 162
Study 28717702 — intervention group
Group type: COMPARATOR
Intervention: Control (negative control subjects)
Number of subjects: 162
Study 25128835 — intervention group
Group type: EXPERIMENTAL
Intervention: NCS-sweetened beverage
Number of subjects: 3
Study 25128835 — intervention group
Group type: COMPARATOR
Intervention: Sugar-sweetened beverage
Number of subjects: 3
Study 25128835 — intervention group
Group type: COMPARATOR
Intervention: Unsweetened beverage
Number of subjects: 3
Study 22189186 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS sensor pads placed over the dorsal, volar, and mobile wad compartments of the forearm during muscle contraction
Number of subjects: 63
Study 22189186 — intervention group
Group type: COMPARATOR
Intervention: Contralateral forearm monitored as an internal control
Number of subjects: 63
Study 20347838 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 90
Study 20347838 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupressure
Number of subjects: 90
Study 20347838 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 18645193 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1,000 mg)
Number of subjects: 21
Study 15909176 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) - 3000 shocks of 0.20 mJ/mm(2)
Number of subjects: 68
Study 15909176 — intervention group
Group type: COMPARATOR
Intervention: Traditional non‐operative measures (control group)
Number of subjects: 68
Study 12877888 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (APRO) at a low dose of 2 Mio KIU in the priming volume
Number of subjects: 30
Study 12877888 — intervention group
Group type: COMPARATOR
Intervention: No Aprotinin (NOAPRO)
Number of subjects: 30
Study 12877888 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (APRO)
Number of subjects: 30
Study 10360185 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug therapy with a protease inhibitor
Number of subjects: 483
Study 10360185 — intervention group
Group type: EXPERIMENTAL
Intervention: No multidrug therapy with a protease inhibitor
Number of subjects: 483
Study 10360185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tritherapy antiretroviral regimens
Number of subjects: 483
Study 10360185 — intervention group
Group type: EXPERIMENTAL
Intervention: Virological efficacy defined as undetectable viral load
Number of subjects: 483
Study 7740525 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (3.4 g eicosapentaenoic and docosahexaenoic acids per day) for six months
Number of subjects: 56
Study 7740525 — intervention group
Group type: COMPARATOR
Intervention: Control group (no omega-3 PUFAs)
Number of subjects: 56
Study 2139385 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/die)
Number of subjects: 38
Study 2139385 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine (10 mg/die)
Number of subjects: 38
Study 7234470 — intervention group
Group type: EXPERIMENTAL
Intervention: brief care (acute treatment aimed at effecting the patient's discharge after about a week)
Number of subjects: 224
Study 7234470 — intervention group
Group type: COMPARATOR
Intervention: standard care (length of stay determined by the clinical team)
Number of subjects: 224
Study 7234470 — intervention group
Group type: EXPERIMENTAL
Intervention: brief care
Number of subjects: 224
Study 7234470 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 224
Study 29803597 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser vaporization (L group)
Number of subjects: 30
Study 29803597 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic stripping (S group)
Number of subjects: 30
Study 29291505 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic drinks targeting a BAC of 0.05%
Number of subjects: 61
Study 29291505 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 61
Study 26703889 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg per day
Number of subjects: 302
Study 26703889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 24406108 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular approach (transvenous)
Number of subjects: 21
Study 24406108 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial approach (robotic-assisted)
Number of subjects: 21
Study 22136068 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP XR 400 mg once daily
Number of subjects: 443
Study 22136068 — intervention group
Group type: COMPARATOR
Intervention: NVP IR 200 mg twice daily
Number of subjects: 443
Study 19927011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 210
Study 19927011 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 210
Study 17966175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel 5% applied twice daily for up to 12 months
Number of subjects: 486
Study 17966175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel 5%
Number of subjects: 486
Study 15910714 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild perioperative hypothermia
Number of subjects: 140
Study 15910714 — intervention group
Group type: COMPARATOR
Intervention: Normothermic patients
Number of subjects: 140